Loading
This large Nordic series showed that gastrointestinal neuroendocrine carcinomas with a Ki-67 below 55 percent respond poorly to platinum-etoposide yet live longer than those above it, which led to the separation of grade 3 neuroendocrine tumours from carcinomas.
Retrospective analysis of 305 patients with advanced gastrointestinal high-grade (grade 3) neuroendocrine carcinoma treated at Nordic centres, examining response to first-line platinum-based chemotherapy and survival by clinical and pathological features.
Response to platinum chemotherapy was 42 percent for Ki-67 of 55 percent or more but 15 percent below it, while survival was longer in the lower Ki-67 group (median 14 versus 10 months); performance status, primary site and lactate dehydrogenase were also prognostic.
The 55 percent Ki-67 threshold and the recognition that well-differentiated grade 3 tumours behave differently from carcinomas, now embedded in the WHO classification, came from this analysis.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/